2012

31/12/12
Präparatewahl in der spezifischen Immuntherapie (SIT): Experten diskutieren über alte Dogmen und neue Evidenz

Die spezifische Immuntherapie (SIT) hat in der jüngeren Vergangenheit einen großen Schritt nach vorne gemacht. Folgen dieser rasanten Entwicklung sind neue Sichtweisen in der Allergologie, die sich in der täglichen Praxis auch...

02/11/12
Stallergenes-Präparate: Neue Daten aus der Routineversorgung und zur Wirtschaftlichkeit

Während des Deutschen Allergiekongresses 2012 in München stellte Prof. Dr. Ralph Mösges, Köln, neue Daten aus der deutschen Praxis zur 5-Gräser-Tablette Oralair® vor. Ebenfalls im Rahmen des Kongresses präsentiert wurden aktuelle...

18/09/12
2012 FIRST HALF-YEAR RESULTS: SALES UP 5.5% AND EBITDA GROWTH (35% OF SALES) STRONG INCREASE IN CASH (82M€)

Antony, France; 11 September 2012 – 6pm.

The Board of Directors approved the financial statements for the first six months of 2012 at its meeting held on 10 September 2012, chaired by Patrick LANGLOIS:

28/08/12
Stallergenes and Aerocrine sign exclusive distribution agreement for NIOX MINO®, an innovative device to allow better diagnosis and monitoring of asthma

Antony (France) and Solna (Sweden), 28 August 2012 – Stallergenes S.A (Euronext Paris CAC small) and Aerocrine AB (OMX Nordic Exchange: AERO) today announce the signing of an exclusive multi-year distribution agreement for...

01/08/12
STALLERGENES: 50 JAHRE KOMPETENZ IN DER IMMUNTHERAPIE

Allergische Erkrankungen, wie die allergische Rhinokonjunktivitis und allergisches Asthma, sind weltweit auf dem Vormarsch. Das Unternehmen Stallergenes hat schon vor 50 Jahren den Kampf gegen diese Erkrankungen aufgenommen. Das...

13/07/12
1ST HALF-YEAR 2012: SALES UP 6% SOLID PERFORMANCE IN A SENSITIVE ECONOMIC SITUATION

Antony, France; 12 July 2012 – 6 pm.

Consolidated sales for the first half of 2012 were € 128.5 million, compared to € 121.7 million for the same period of the previous year. The European market was adversely affected by the...

13/06/12
Patrick Langlois appointed non executive chairman of the board of directors of Stallergenes

Antony (France), 13 June 2012 – Stallergenes (Euronext Paris CAC small) announces the appointment of Patrick Langlois as non executive Chairman of the Board of Directors, with effect from 1st July 2012.

21/05/12
Stallergenes remains committed to the recognition of innovative pharmaceutical companies and has joined G5 Health

Antony (France), 21 May 2012 – Stallergenes S.A. (Euronext Paris CAC small) today announces that it has joined G5 Health, a professional association that brings together the leading French healthcare and life science companies.

04/05/12
Stallergenes announces positive clinical results for its house dust mites immunotherapy tablet

Antony (France), 4 May 2012 – Stallergenes S.A (Euronext Paris CAC small) today announced results of a clinical study (VO67.10) of its house dust mites sublingual immunotherapy tablet, conducted in an Environmental Exposure...

17/04/12
Allergische Rhinitis: Neue App unterstützt Betroffene

Menschen mit Atemwegsallergien können die Schwere ihrer Erkrankung oft nicht einschätzen. Die neue App „Allergy Track“ von Stallergenes hilft ihnen dabei, ihre Allergie zu dokumentieren und bei Veränderungen frühestmöglich einen...

04/04/12
Stallergenes has identified two candidate biomakers of early efficacy of allergen immunotherapy

Antony (France), 2 April 2012 – Stallergenes SA (Euronext Paris CAC small) today announced the publication1 in the April issue of Journal of Allergy and Clinical Immunology (JACI) of an article presenting the identification of...

23/03/12
Stallergenes continues its strategic international expansion with the successfull registration in Canada of Oralair tablet for grass pollen

Antony (France), 21 March 2012 - Stallergenes SA (Euronext Paris CAC small) announced today that Health Canada has approved Oralair™.